Furthermore, we are delighted to learn that a PBT study, TORPEd O, that was first presented to one of CTRad’s Proposals Guidance meetings back in 2016 has recently been funded and is now entering the trial set up stage.
Although PBT is new to the UK, the technology has been in use for a while in some other countries, in the USA for example, but high-quality evidence to support its use is unfortunately lacking.
NCRI’s CTRad recently published a review of practice changing radiotherapy clinical trials across five tumour sites that have been performed worldwide in radiotherapy over the last 20 years and found 44 conventional radiotherapy trials involving 50,000 patients.
Clinical trials are often complex, multi-centre projects carried out across disparate geographical locations and involving large numbers of patients.
With PBT in the UK, there are added complexities for research – the patient pathway will change for patients who will receive PBT at one of the two PBT centres whereas the standard of care treatment will be delivered locally; we need innovative clinical trial methodology and there is a limit on the research capacity at the PBT centres.
We recently published an eight-point framework for the development and delivery of high quality clinical trials in PBT and will be working with both the UK and international research communities to implement this.
We we must work with some speed in order to exploit the opportunities that this new and promising technology provides.